A Wednesday night earnings report left big questions about how the spending reductions would affect the company.

Genomics (NASDAQ:TXG – Get Free Report) had its price objective reduced by equities researchers at Stifel Nicolaus from ...

Analysts at Leerink Partnrs decreased their Q1 2025 earnings estimates for shares of 10x Genomics in a research note issued to investors on Thursday, February 13th. Leerink Partnrs analyst P. Souda ...

X Genomics Inc . (NASDAQ:TXG) reported its Q4 2024 earnings, revealing a larger-than-expected loss per share and a decline in revenue compared to the previous year. The company posted an EPS of -$0.40 ...

On Wednesday, 10x Genomics Inc (NASDAQ:TXG) reported a fourth-quarter EPS loss of $(0.40), missing the consensus estimate of ...

Barclays lowered the firm’s price target on 10x Genomics to $18 from $19 and keeps an Overweight rating on the shares. The firm expects the ...

Stifel lowered the firm’s price target on 10x Genomics (TXG) to $18 from $21 and keeps a Buy rating on the shares. The funding environment ...

2025 Stock Picks. In this article, we are going to take a look at where 10x Genomics, Inc. (NASDAQ:TXG) stands against the other stocks in Cathie Wood's portfolio. Cathie Wood is one of Wall ...

CEO Serge Saxonov highlighted strong growth across platforms, with total revenue for Q4 2023 reaching $184 million, an 18% increase year-over-year. Spatial products contributed significantly, with ...